semaglutide dawsonville Flex-Dose 3 mL Injectable 2.5 mg/mL Novo Nordisk sues two pharmacies

If successful across all indications, retatrutide could receive approval for weight management , type 2 diabetes, cardiovascular risk reduction, knee osteoarthritis, and liver disease

Out of the entire trial

You can read my disclaimer on my blogs side panel.

From a safety standpoint, retatrutide's known adverse effect profile from phase II trials includes: Nausea, vomiting, and diarrhoea (gastrointestinal effects common to GLP-1 receptor agonists) Reduced appetite and potential nutritional deficiencies with prolonged use Elevated heart rate observed in some trial participants Pancreatitis and gallbladder disease , which are recognised class cautions for GLP-1based therapies and should be considered in the context of retatrutide, although retatrutide-specific data remain limited Thyroid C-cell changes , observed in rodent studies with GLP-1 receptor agonists